Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Income from Continuing Operations (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Income from Continuing Operations for 8 consecutive years, with 84215000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 13.04% year-over-year to 84215000.0; the TTM value through Mar 2026 reached 359485000.0, down 29.09%, while the annual FY2025 figure was 349769000.0, 33.56% down from the prior year.
  • Income from Continuing Operations hit 84215000.0 in Q1 2026 for Kymera Therapeutics, up from 97986000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 19364000.0 in Q4 2023 and bottomed at 97986000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 60177941.18, with a median of 57550000.0 recorded in 2023.
  • Year-over-year, Income from Continuing Operations skyrocketed 49.95% in 2023 and then crashed 317.34% in 2024.
  • Kymera Therapeutics' Income from Continuing Operations stood at 38689000.0 in 2022, then skyrocketed by 49.95% to 19364000.0 in 2023, then plummeted by 317.34% to 80814000.0 in 2024, then decreased by 21.25% to 97986000.0 in 2025, then grew by 14.05% to 84215000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 84215000.0, 97986000.0, and 92619000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.